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INTRODUCTION 
The conventional treatment for hepatocellular carci-
noma (HCC) has been surgical resection. typically by 
segmentectomy. lobectomy. or trisegmentectomy. The 
large majority of patients. however. cannot have their 
tumors resected. either because of underlying cirrhosis 
and liver damage. making resection hazardous. or be-
cause of the multifocal or bilobar spread of the hepatoma. 
In those patients with resectable tumors. the recurrence 
rates and survival have been found to depend mainly on 
stage of disease [1.2]. The best results have been with 
TNM stage I disease. with stage II and resectable stage III 
disease typically having < 30% survival at 3 years. Fac-
tors adversely intluencing prognosis have included dif-
fuse disease. multi focal primaries. vascular invasion. and 
lymph node involvement. 
Causes of Recurrence After Resection 
The evidence from liver transplantation specimens in-
dicates that much clinically evident hepatoma is either 
multi focal or widespread. This suggests that disease that 
has been diagnosed by angiography. ultrasound. mag-
netic resonance imaging (MRl) or computed tomography 
(CT) scan consistently underestimates the amount of 
spread of disease in the liver. Thus. there is a reasonable 
probability of undetected residual microscopic disease in 
the remaining liver. which would account for the high 
recurrence rates. 
Liver Transplantation 
The results of liver transplantation for stages I and II 
HCC have been very encouraging. with high 3- and 
5-year survival rates [I .2J. However. for stage IV A and 
to a lesser extent for stage III disease. recurrence rates in 
the new liver and in other organs still remain very high. 
For stage IV A. there are few 2-year survivors. The causes 
of these high recurrence rates are not immediately appar-
cnt. Likely explanations include the presence of micro-
scopic metastases at the time of transplantation for ad-
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vanced stage disease. vascular invasion with seeding of 
the blood stream during surgical manipulation. and the 
effect of immunosuppression in enhancing the growth of 
occult microscopic disease. 
Chemotherapy of HCC 
A considerable literature on single and combination 
drug chemotherapy for HCC has recently been reviewed 
[3]. In summary. no consistent response rates of > 20% 
nor impact on survival have been demonstrated. There is. 
thus. no standard chemotherapy treatment for HCC that 
can be justified by published response rates. Although 
earlier studies suggested that doxorubicin was a useful 
agent. subsequent reports have not substantiated this [3]. 
In contrast to the responses for systemically delivered 
chemotherapy, many groups have reported > 40% re-
sponse rates for several agents and combinations of 
agents when delivered regionally [3-6J. The principle 
underlying this concept is that whereas approximately 
80% of the oxygen-carrying blood to the normal liver is 
delivered via the portal vein. HCCs derive their blood 
supply primarily from an arterial supply. usually through 
a neo-vasculature. This permits the selective delivery of 
drugs to the tumor with a relative sparing of the normal 
liver. Even damage to the hepatic artery does not neces-
sarily compromise the residual liver. at least when the 
residual liver is normal. 
REGIONAL CHEMOTHERAPY FOR HCC 
The selective nutrition of tumors in the liver from the 
hepatic artery rather than the portal vein has given rise to 
several approaches for selectively interfering with tumor 
growth by local means. These have included direct he-
patic artery ligation. embolization or thrombosis of the 
hepatic artery. or intermittent obstruction of the hepatic 
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artery. While responses have been reported with obstruc-
tion of the hepatic artery alone. they have normally been 
of relatively short duration. In addition. this type of treat-
ment can be difficult and may be associated with hepatic 
decompensation. in the presence of chronic hepatitis or 
cirrhosis. particularly if the main portal vein is ob-
structed. 
Arterial Chemotherapy 
Several agents have been reported to induce tumor 
responses when injected or infused into the hepatic ar-
tery. These include 5-tluorouracil (5-FU), 5-FUdR. mit-
omycin C. doxorubicin. neocarzinostatin. and cis-plati-
num. Few studies have reported an impact on survival. 
however. A large number of studies. most notably from 
Japan. have reported consistently higher response rates in 
the region of 50%. with single or combination drugs 
when combined with some form of embolizing agent 
.:.:iven into the hepatic artery. These agents have included 
,ullagen. starch. glass beads. degradable starch micro-
spheres. the poppy seed oil Lipiodol (Ethiodol). gelatin. 
and even blood clots. Most studies have not been ran-
domized. so that it is not usually easy to determine the 
effect of the embolizing agent on the chemotherapy with 
which it is mixed. In addition. the mechanical obstruction 
due to the embolizing agent is often short lived. Some 
agents. such as Lipiodol. essentially cause no hepatic 
arterial obstruction. or at least only a very transient one. 
Intra-Lesional Injections 
A large literature exists on the direct injection of etha-
nol into small HCCs [71. This appears to be a rather safe 
modality of treatment. and high response rates have been 
reported. However. since only a single lesion or small 
numbers of lesions can realistically be injected. the inci-
dence Dr new hepatomas occurring in the cirrhotic livers 
that have been injected is quite high. Multiple treatments 
are normally given several times a month. but the treat-
ment is cheap and can be done in an outpatient setting 
under ultrasonography guidance. and for small lesions at 
least. high response rates are reported. For other malig-
nancies. there is a long history of intra-Iesional injection. 
particularly for melanoma. for which BCG and polyI: 
polyC injections have been reported to produce high rates 
of single lesion involution. It is probable that for any 
tumor. including HCC. direct injection of irritants will do 
the same. The limitation of this technique is that it cannot 
be performed adequately for large or multiple lesions. 
HORMONAL THERAPIES 
The high male to female incidence of HCC and the 
presence of receptors for androgens. epidermal growth 
factor (EGFL transforming growth factor alpha (TGFu). 
and glucagon in HCC has led to the idea that growth 
factor or hormonal manipulation may alter growth. Re-
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cent reports on the use of tamoxifen have led to a sugges-
tion of an effect on survival. but no objective response 
rates of tamoxifen alone have been reported. Anti-andro-
gen and luteinizing hormone releasing hormone (LHRH) 
antagonist therapies are currently under investigation in 
controlled clinical trials in the EORTC. but no benefit has 
been so far reported. More hormonal agents are likely to 
be tested in the next few years. 
At the University of Pittsburgh Liver Transplant De-
partment, 29 patients were recently treated with tamox-
ifen 20 mg bid orally. Inclusion criteria were failure of 
prior chemotherapy or inability to give chemotherapy 
because of underlying liver disease. usually due to 
Child's class C cirrhosis. Of 29 patients treated. 28 are 
currently evaluable for response. There were no respond-
ers. and average time to progression has been 3 months. 
In this series of patients with advanced disease. no activ-
ity for tamoxifen has been found. 
COMBINATION REGIONAL CHEMOTHERAPY 
FOR ADVANCED STAGE HCC 
From 1990 to 1992. 83 patients at the University of 
Pittsburgh were enrolled in a study with a protocol inves-
tigating the role of doxorubicin and cis-platinum in the 
treatment of advanced stage HCC. All patients had bi-
opsy proven HCC. Patients were excluded who had liver 
failure. non-correctable coagulopathy. or encephalopa-
thy. The regimen consisted of doxorubicin 4 mg/ml and 
cis-platinum 100 mg/ml mixed in 100 ml normal saline 
and administered into the hepatic artery for 30 minutes. 
Usually only a right or left hepatic artery infusion was 
given. unless there was massive bilobar disease. in which 
case occasional patients had the proper or common he-
patic artery cannulated. Cycles were repeated every 28 
days for a minimum of three treatments (evaluable for 
response). Interferon-alpha was also administered subcu-
taneously as 3 million units three times a week continu-
ously throughout the treatment. This was included in the 
regimen because of its synergistic cytotoxicity with both 
doxorubicin and cis-platinum and because of its action in 
suppressing virus hepatitis. Forty-eight patients are cur-
rently evaluable for response. of whom 29 have achieved 
greater than 50% reduction in the product of two perpen-
dicular diameters of their tumors. measured by CT scan. 
to produce a 60% response rate. An additional five pa-
tients with fibrolamellar HCC were also treated. of whom 
none had a response. In a large experience of 83 patients 
treated on or off protocol. 3 had chemotherapy-induced 
hepatic decompensation. An additional six had chemo-
therapy-induced worsening of their liver function. which. 
however. stabilized. Abdominal pain was seen in only 
five patients and fever in two. A transient chemical hepa-
titis was seen in 24 patients. which almost invariably 
disappeared within 10 days of treatment. This high re-
sponse rate was also associated with an increased patient 
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survival in those patients who responded compared with 
those who did not [6]. For non-responding patients. the 
50% survival was reached at 6 months. However. in 
responding patients. there was one death at 3 months and 
one at 12 months. All other responding patients are cur-
rently alive. with the longest survivor currently at 26 
months. 
Several new conditions were introduced with this pro-
tocol. These included full systemic doses of chemother-
apy given into the hepatic artery; an escalating dose ap-
proach was used to limit hepatic decompensation: therapy 
was based primarily upon use of cis-platinum: systemic 
interferon was added: repeated long-term treatments were 
used. because of the often long doubling times: emboliza-
tion was omitted. to permit repeated regular re-treat-
ments. Because of initial experience of hepatic dysfunc-
tion with the chemotherapy. and our inability to predict 
tolerance to this chemotherapy. an escalating dosage ap-
proach was taken. The first treatment was given at 50% 
of the calculated dose. the second at 75%. and the third 
and subsequent treatments at 100% of calculated dose. 
A Randomized Perspective Study of Cis-Platinum 
and Doxorubicin Plus or Minus Lipiodol Infused 
Into the Hepatic Artery for Advanced Staged HCC 
A current ongoing study at the University of Pittsburgh 
compares cis-platinum and doxorubicin with or without 
Lipiodol. Currently. 46 evaluable patients have been en-
rolled in the study, 23 in each arm. There have been 
14/23 responders in the Lipiodol arm (61 %) and 12/23 
responders in the solution arm (52%). This is not yet 
statistically significant. Interestingly, we again see a sur-
vival advantage for responders in both groups. There is a 
257c mortality for responders at I year compared with a 
757c mortality for non-responders. Currently. no major 
advantage has been found for the addition of Lipiodol in 
this study. 
SPECIAL PROBLEMS ASSOC[ATED WITH 
CHEMOTHERAPY OF HCC 
Most types of tumor tend to arise in an otherwise 
basically healthy body. However. HCC usually arises on 
the basis of chronic hepatitis or cirrhosis. and thus in a 
diseased major organ. The organ concerned. namely the 
liver. is also the main site of detoxification of xenobiot-
ics. and this poses special hazards in the treatment with 
cytotoxic chemicals of patients with HCC. In addition. 
the sequelae of portal hypertension and splenomegaly are 
particular concerns for chemotherapists. These include 
hleeding from esophageal varices and the possibility of 
their exacerbation. splenomegaly-associated thrombocy-
topenia. and splenomegaly-associated leukopenia. The 
recent availability of granulocyte colony stimulating fac-
tor has vastly increased the margin of safety with leuko-
penia. Curiously. we rarely encounter dramatic drops in 
platelet count. despite low platelet starting levels. The 
reasons for this are unclear. In addition. the decreased 
synthetic function is often associated with hypo-pro-
thrombinemia, and the decreased catabolic functions of 
the liver are associated with an inability to detoxify the 
chemotherapeutic agents. resulting in an often dangerous 
increase in plasma half-life. Finally. the decreased he-
patic reserve in an already damaged liver appears to ren-
der the liver particularly sensitive to further damage by 
chemotherapeutic agents, often resulting in at least tran-
sient increases in bilirubin and sometimes permanent he-
patic decompensation. 
CHEMOTHERAPY FOR HCC: SOME 
SPECIFIC CONSIDERATIONS 
Intrinsic Drug Resistance 
It has been known for over 50 years that chronic injury 
to the liver results in a resistance to toxicity induced by a 
variety of chemical agents [8]. Subsequently. it was 
shown that polycyclic hydrocarbon carcinogens and other 
carcinogens could induce both tumors as well as resis-
tance to toxic damage. It then became apparent that resis-
tance to inhibitors of growth was an innate property of 
carcinogen-induced hepatocellular carcinomas. both in 
vivo and in vitro. This has been associated with an altered 
biochemical pattern of the hepatomas. which includes a 
decrease in phase I enzymes. including cytochromes 
p-450 and mixed function oxygenases: an increase in 
several phase II enzymes. including UDP-glucuronyl 
transferase. glutathione-S-transferases. gamma-glutamyl 
transferase: and an increase in some other detoxifying 
enzymes. including epoxide hydrolase and DT-diapho-
rase. Increases in expression of specific genes associated 
with drug resistance have also been found. including 
increased mRNA levels for multiple drug resistance gene 
I. metalathionein. gamma-glutamyl transpeptidase. glu-
tathione-S-transferase 7T, epoxide hydrolase, and the heat 
shock cognate genes. Thus, it is not surprising that sys-
temic chemotherapy has failed to produce consistent 
meaningful response rates for this disease. Probably a 
whole new generation of drugs is needed. which does not 
depend upon cytotoxicity for their mechanisms of action. 
In the interim. a rational approach for increasing the drug 
concentration is either regional injection of chemother-
apy. increasing the concentration of cytotoxic chemo-
therapy directly in the region of the tumor. or else contin-
uous infusion into the hepatic artery. There is little 
literature on the latter modality for HCC. however. 
Tumor Doubling Times 
The reported doubling times for human hepatomas is 
quite variable. ranging from 30 to over 300 days. This 
has strong implications for cancer chemotherapy. For a 
tumor with a doubling time of 30 to 90 days. only a small 
fraction of the cells will be in the DNA synthesis part of 
the cell cycle on the day of chemotherapy. Thus, only a 
small fraction of the cells will be in the sensitive phase of 
the cell cycle. A practical consequence of this is that 
multiple repeated treatments will be required to impact on 
a greater proportion of the cells in the tumor. A correlate 
of this is that embolization, although it may obstruct the 
blood supply temporarily, can also interfere with re-
peated regular re-treatments. This needs to be taken into 
account in the design of regimens for HCC. 
Vascular Access and Flow 
Repeated instillation of toxic drugs into the hepatic 
artery or its branches often results in intimal damage. 
Usually this is minor or transient. but can induce throm-
bosis, which can negatively impact on the safety of resec-
tion and occasionally of transplant. Often, aberrant blood 
vessels feed the tumor. which are not always easily ac-
cessed by the vascular radiologist. In addition, reverse 
!low in the liver consequent on portal hypertension can 
result in centrifugal blood tlow, with limited amounts of 
chemotherapy being delivered to the tumor. Often, the 
hepatoma is bilobar or diffusely involving many lobes. It 
is difticult to know the optimal means of infusing chemo-
therapy in these circumstances. The choices include in-
fusing chemotherapy only into the proper or common 
hepatic artery, in the hope of drug accessing all of the 
tumor. although that in tum will depend upon the vagar-
ies of the blood supply to the various tumor nodules: 
splitting the tumor dose among the various branches of 
the hepatic artery: or administering chemotherapy to spe-
cific arteries on sequential courses of chemotherapy. Our 
own practice is to try to concentrate the chemotherapy on 
the largest area of tumor initially, and not to treat the 
whole liver. in order to decrease the likelihood of hepatic 
decompensation. If there is bilobar disease, we will sub-
sequently alternate sides for treatment. This also has the 
effect of increasing the concentration of chemotherapy on 
the tumor nodule being treated. The vagaries of blood 
tlow can also result in back tlow of chemotherapy into the 
mesenteric artery, gastric arteries, or blood vessels feed-
ing the gall bladder. Consequences of this include ab-
dominal pain from bowel irritation, exacerbation of pep-
tic ulcer disease. or chemical cholecystitis. 
COMBINED MODALITY THERAPY FOR HCe 
Given the high recurrence rates for advanced stages of 
HCC after either resection or transplantation, and the 
high response rates being seen by many groups for ag-
gressive regional chemotherapy, it would seem reason-
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able to combine these approaches. Studies with pre-
operative neo-adjuvant or post-operative adjuvant che-
motherapy for resectable HCC have been published from 
Japan, with contlicting results. No large or multi-center 
study has yet been published. At the University of Pitts-
burgh, we recently started a program of neo-adjuvant 
chemotherapy with a minimum of three cycles of intra-
arterial doxorubicin and cis-platinum prior to placing pa-
tients on a waiting list for their liver transplant. Patients 
then continue their monthly treatment cycles until a donor 
liver is found. So far, II patients have been treated with 
this combination who have a minimum of 12 months 
follow-up post-transplant. or who have died. One patient 
died of recurrent disease within 12 months. One patient 
developed newly recurrent disease, giving a 91 % I-year 
survival. During the same period of time and under the 
identical immunosuppressant regimen with the novel 
agent FK506. an additional 14 patients were transplanted 
without prior neo-adjuvant chemotherapy. This was not 
given either because of patient refusal or (usually) poor 
liver function and Child's class C cirrhosis. Nine of these 
patients developed recurrences within 12 months of trans-
plant (64% recurrence rate at I year), and eight had died 
with tumor recurrence in I year (43% I-year survival). 
This small pilot experience is encouraging [9], but a 
randomized study will be needed to test this idea formally. 
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